{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.28","upperLimit":"2.69","value":"1.30"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"}],"units":"Participants"}],"title":"Colorectal Cancer"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.62","upperLimit":"1.51","value":"1.25"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"title":"Gastroesophageal Cancer"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.28","upperLimit":"1.91","value":"1.31"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"}],"units":"Participants"}],"title":"Non-Small Cell Lung Cancer"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.18","upperLimit":"2.10","value":"1.31"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"title":"Ovarian Cancer"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.45","upperLimit":"2.66","value":"2.30"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"}],"units":"Participants"}],"title":"Prostate Cancer"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.72","upperLimit":"2.76","value":"1.51"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"title":"Squamous Cell Carcinoma of Head and Neck"}],"denoms":[{"counts":[{"groupId":"OG000","value":"103"}],"units":"Participants"}],"description":"PFS defined as the time from date of first dose to the first observation of disease progression or death due to any cause. Progressive Disease (PD) was defined as at least 20% increase in sum of longest diameter of target lesions and minimum 5 millimeter (mm) increase over nadir. For participants who were not known to have died or to have progressed as of the data inclusion cutoff date, PFS were censored at the date of the last objective progression-free disease assessment prior to the date of any subsequent systemic anticancer therapy.","dispersionType":"90% Confidence Interval","groups":[{"description":"LY2523355: Dose determined by participant body surface area: 5 milligrams/square meter(mg/m²) or 6 mg/m², administered intravenously as a one hour infusion on Days 1, 2 and 3 of a 21 day cycle for up to 2 cycles (4 cycles for prostate cancer participants). Additional cycles administered based on participant response assessment.\n\nPegfilgrastim: 6 milligrams (mg), administered subcutaneously approximately 24 hours after third dose of LY2523355 on Day 4 of each 21-day cycle, for up to 2 cycles of LY2523355 administration (4 cycles for prostate cancer participants). Additional cycles of LY2523355 administered based on participant response assessment.","id":"OG000","title":"LY2523355"}],"paramType":"MEDIAN","populationDescription":"All enrolled participants who received at least 1 dose of study drug. Percentage (%) of participants censored were colorectal cancer 5.9%; gastroesophageal cancer 0.0%, non-small cell lung cancer 3.4%, ovarian cancer 15.4%, prostate cancer 16.7%, and squamous cell carcinoma of the head and neck 15.4%.","reportingStatus":"POSTED","timeFrame":"Date of enrollment to progressive disease or death due to any cause up to 36 weeks post-enrollment","title":"Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"months"}